// App-Quantinova.ai

598 : Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC).

Researchers

Presenter

  • Nizar M. Tannir

Principal Investigators

  • Robert A. Figlin

  • Martin Eric Gore

  • Dror Michaelson

  • Robert J. Motzer

  • Camillo Porta

  • Brian I. Rini

  • Caroline J. Hoang

  • Xun Lin

  • Bernard Escudier

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • IRCCS San Matteo University Hospital Foundation, Padua, Italy

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Pfizer Inc, New York, NY

  • Pfizer Oncology, La Jolla, CA

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • United States

  • United Kingdom

  • Italy

  • France

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Sunitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved